Looking Forward At FDA: Hamburg’s Farewell Notes Challenges; Califf’s First Remarks Focus on Pediatrics
This article was originally published in RPM Report
FDA Commissioner Margaret Hamburg is leaving the agency on a high note – and taking the opportunity to urge stakeholders to avoid the temptation to push for changes that will “”weaken or undermine” the agency. Meanwhile, FDA's new Deputy Commissioner of Medical Products Robert Califf makes his first formal remarks in that role during a stakeholder meeting on pediatric research.
You may also be interested in...
Transition Time: CMS Deputy Slavitt Takes Over As Interim Agency Head; FDA Enters Caretaker Phase Next
Andy Slavitt will be the caretaker head of CMS for the remainder of the Obama Administration, reinforcing the focus on smooth operations and close alignment with the White House health team. Duke’s Robert Califf joins FDA as Deputy Commissioner for Medical Products just in time for that agency to enter the caretaker phase.
A decision made more than 15 years ago by CMS to require drug insurance plans to cover all drugs for six specific diseases has proven impervious to change. But will the protected classes remain if Part D is reformed more broadly?
A Senate hearing on the US COVID-19 response recalled Kessler’s tenure as FDA commissioner a quarter century ago – and included some reminders that things have changed.